Randomized Clinical Trial of a Pharmaceutical Care Program in Chronic Patients Users of an Emergency Department
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Enrollment
- 100
- Primary Endpoint
- Mortality
Overview
Brief Summary
The study aims to assess the clinical and economic impact of a pharmaceutical care program initiated in the Emergency Department versus conventional follow-up of patients with decompensated heart failure/COPD.
Detailed Description
Clinical trial aimed to assess the impact of a pharmaceutical care program initiated in the Emergency Department vs standard care in patients with heart failure and/or COPD, conducted at the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) between Jan12-Feb13.
The researchers hypothesize that a systematic, standardized pharmaceutical care program may be related to a lower frequency of drug related problems (DRP). Moreover, the investigators also hypothesize that 6-month mortality, the average length of the hospital stay, and its related cost may also be decreased.
This study was approved by the Hospital de la Santa Creu i Sant Pau Ethics Committee. Written informed consent will be obtained from the participants .
The study will include 100 patients who fulfill all the inclusion criteria, described in the Eligibility Section.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: 65 years and over
- •Admission in the Emergency Department for a period equal to or higher than 12 hours;
- •Number of home medication equal to or higher than four;
- •Diagnose in the Emergency Department episode: decompensated heart failure and/or decompensated COPD.
Exclusion Criteria
- •Suffering from dementia, severe mental disorders and living in nursing homes.
Outcomes
Primary Outcomes
Mortality
Time Frame: 6-month after inclusion
Patients who died during the following 6 months after inclusion
Drug Related Problems (DRP)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days
Patient health outcomes that are not consistent with the objectives of pharmacotherapy and are associated with the use or errors in the use of medicines
Readmissions
Time Frame: 6-month after inclusion
Number of visits (emergency department/hospitalization) due to HF and/or COPD decompensation after the first episode (inclusion in the study), in the next 1180 days.
Average length of the hospital stay
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days
Duration of the stay (in hours) from the emergency episode until discharge from the hospital
Average cost of hospital stay
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days
Average money spent per patient in Euros.
Secondary Outcomes
No secondary outcomes reported
Investigators
Ana Juanes
Pharmacist
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau